MDM2 and cancer: As our investigation illustrated a pronounced anti-tumoral effect of Idasanutlin, Milademetan, and Nutlin-3a in the p53-mutated TNBC cell lines and, due to the inactivating p53 mutation, this effect is likely independent of an interference with p53-MDM2 interactions, we were interested to know whether the reduction in cancer cell viability occurs independently of cellular p53 expression.